Pacritinib
GEMFIN-MF-PACRI 2401
Phase 2 small_molecule active
Quick answer
Pacritinib for Patients with myelofibrosis and platelets counts between 50 - 120 x 10e9/L is a Phase 2 program (small_molecule) at Meda AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Meda AB
- Indication
- Patients with myelofibrosis and platelets counts between 50 - 120 x 10e9/L
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active